BioSpace News Archive

ChromaDex Corp. announced the results of four recently published preclinical studies, highlighting new findings for its patented nicotinamide riboside healthy aging nutrient.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced that Kevin Cook will join as the Company’s Chief Financial Officer, effective June 21, 2021.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced the appointment of Brooke Story to its Board of Directors.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced that it has achieved a milestone associated with the development of AT-527 and expects to receive a related payment under its license agreement with Roche of $50 million.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced the appointment of Laura L. Parks, Ph.D., to the company’s board of directors.

People living with HIV are less likely to mount an adequate immune response, which may put them at higher risk for both serious COVID-19 illness and reduced response to COVID-19 vaccination.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that NIDA has resumed recruiting patients for its proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist.

Cybin Inc.today announced that it has selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004.

InSphero AG today officially launched a pre-competitive consortium that brings together representatives from pharmaceutical companies engaged and invested in the development of cross-species drug testing.

PureTech Health plc today announced the acquisition of the remaining 22 percent of shares outstanding in its Founded Entity, Alivio Therapeutics (“Alivio”)